7 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationNeovascular Age-related Macular Degeneration; nAMDRecruitingPhase 32026-09-29NCT07614776
Extension Study for the Port Delivery System With Ranibizumab (Portal)Neovascular Age-Related Macular DegenerationRecruitingPhase 32026-09-28NCT03683251
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationGeographic Atrophy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, age-related macular degeneration, eye disorder, macular degeneration, nervous system disorder, retinal degeneration, retinal disorder, vision disorder, wet macular degenerationActive, not recruitingPhase 22026-09-22NCT05230537
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationGeographic Atrophy Secondary to Age-related Macular DegenerationRecruitingPhase 22026-09-09NCT07441642
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorderActive, not recruitingPhase 22026-08-19NCT04567550
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDNeovascular Age-Related Macular Degeneration (nAMD)Enrolling by invitationPhase 22026-08-05NCT05210803
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNeovascular Age-related Macular DegenerationActive, not recruitingPhase 32025-06-17NCT06495918